Evidence map›Paper›PMID 27030393›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2016

The disintegrin, trimucrin, suppresses LPS-induced activation of phagocytes primarily through blockade of NF-κB and MAPK activation.

Yu-Chun Hung, Chun-Chieh Hsu, Ching-Hu Chung, Tur-Fu Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. CC5 and CC8, Two Disintegrin Isoforms fromInternational journal of molecular sciences · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yu-Chun HungGraduate Institute of Pharmacology, College of Medicine, National Taiwan University, No1, Sec1, Jen-Ai Rd, Taipei, Taiwan.
Chun-Chieh HsuGraduate Institute of Pharmacology, College of Medicine, National Taiwan University, No1, Sec1, Jen-Ai Rd, Taipei, Taiwan.
Ching-Hu ChungDepartment of Medicine, Mackay Medical College, New Taipei, Taiwan.
Tur-Fu HuangGraduate Institute of Pharmacology, College of Medicine, National Taiwan University, No1, Sec1, Jen-Ai Rd, Taipei, Taiwan. turfu@ntu.edu.tw.
National Taiwan University · TWMackay Medical College · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to antiplatelet activity, disintegrin, a small-mass RGD-containing polypeptide, has been shown to exert anti-inflammatory effects but the mechanism involved remains unclear. In this study, we report that trimucrin, a disintegrin from the venom of Trimeresurus mucrosquamatus, inhibits lipopolysaccharide (LPS)-induced stimulation of THP-1 and RAW 264.7 cells. We also investigate the underlying mechanism. Trimucrin decreased the release of proinflammatory cytokines including tumor necrosis factor α (TNFα), interleukin-6 (IL-6), nitric oxide, and reactive oxygen species (ROS), and inhibited the adhesion and migration of LPS-activated phagocytes. Trimucrin significantly blocked the expression of nuclear factor kappaB (NF-κB)-related downstream inducible enzymes such as inducible nitric oxide synthase (iNOS) and COX-2. In addition, its anti-inflammatory effect was associated with the decreased mitogen-activated protein kinase (MAPK) phosphorylation. Furthermore, trimucrin concentration dependently inhibited LPS-induced phosphorylation of focal adhesion kinase (FAK), PI3K, and Akt. Trimucrin also reversed the DNA-binding activity of NF-κB by suppressing the LPS-induced nuclear translocation of p65 and the cytosolic IκB release. Flow cytometric analyses showed that trimucrin bound to cells in a concentration-dependent manner. The anti-αVβ3 mAb also specifically decreased the binding of fluorescein isothiocyanate (FITC)-conjugated trimucrin. Binding assays demonstrated that integrin αVβ3 was the binding site for trimucrin on THP-1 and RAW 264.7 cells. In conclusion, we showed that trimucrin decreases the inflammatory reaction through the attenuation of iNOS expression and nitric oxide (NO) production by blocking MAP kinase and the NF-κB activation in LPS-stimulated THP-1 and RAW 264.7 cells.

Indexed as

AnimalsAnti-Inflammatory AgentsBinding SitesCell AdhesionCell Line, TumorChemotaxisCrotalid VenomsCyclooxygenase 2CytokinesDisintegrinsDose-Response Relationship, DrugEnzyme ActivationHumansInflammation MediatorsIntegrin alphaVbeta3LipopolysaccharidesAnti-Inflammatory AgentsCrotalid VenomsCyclooxygenase 2CytokinesDisintegrinsInflammation MediatorsIntegrin alphaVbeta3LipopolysaccharidesMitogen-Activated Protein KinasesNF-kappa BNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanNos2 protein, mousePeptidesPTGS2 protein, humanPtgs2 protein, mouseTrimeresurus venomstrimucrinIntegrin αVβ3LPSPhagocyteSignaling transductionSnake venom disintegrin

Identifiers

PMID27030393
OpenAlexW2325254199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.